Dr. R. Sreedhara, MD, FACP

American Board Certified In Internal Medicine & Nephrology

Associate Professor of Nephrology, Institute of Nephro-Urology, Bangalore

Formerly Associate Professor of Clinical Medicine at StateUniversity of New YorkHealthSciencesCenter at Brooklyn, New York, USA

Consultant Nephrologist, WockhardtHospital & The BangaloreHospital, Bangalore

Residence:

139, 32nd Cross, 11th MainMobile: +91 (80) 98801 50813

Jayanagar 4th Block EastHospital: +91 (80) 66214120

Bangalore 560011, Indiae-mail:

1

R. Sreedhara, MD, FACP, DAB-Med (USA), DAB-Neph (USA). Resume Updated March 2011, page1of 11

education
College
1979-81
Medicine
1981-86 / The NationalCollege, Bangalore, India. Fourth Rank in the State among 117,000 students.
MysoreMedicalCollege, University of Mysore, India. Passed in First Class. Seventh Rank in the University. Degree: MBBS
POST-GRADUATE qualifications
1991
1994
2004 /
  • Diplomate in Internal Medicine, American Board of Internal Medicine.
  • Diplomate in Nephrology, American Board of Internal Medicine.
  • Re-Certification in American Board of Internal Medicine & Nephrology.

Clinical Training
1986-87
1988-91
1991-94 /
  • Rotating Internship, K.R. & Combined Hospitals, Mysore, India.
  • Residency in Internal Medicine, Georgetown Department of Medicine at the District of Columbia General Hospital, Washington DC.
  • Nephrology Fellowship, VanderbiltUniversitySchool of Medicine, Nashville, Tennessee, USA.

Academic Appointment
1999-2002
2007 – / Associate Professor of Clinical Medicine, State University of New York at BrooklynHealthSciencesCenter, Brooklyn, New York, USA.
Associate Professor of Nephrology, Institute of Nephro-Urology, Bangalore.
research Appointment
2002-2004
2004-current / Medical Director, Outcomes Research International, Inc., Florida.
Medical Director, Outcomes Clinical Research India, Bangalore.
Teaching Experience
1994-2000
2004-2006
2007 – / Third and Fourth Year Medical Students from State University of New York at Brooklyn, New York & St. George’s Medical School rotating through the Long Island College Hospital.
Residents and Nephrology Fellows at the Long IslandCollegeHospital: Teaching Rounds, Patient Management Rounds, House-staff conferences, Internal Medicine Board Review.
Research Advisor for Nephrology fellows, Internal Medicine residents and Medical students in the Division of Nephrology and in the Department of Internal Medicine at the Long IslandCollegeHospital.
Visiting faculty for the DNB program in Nephrology at NU Trust, Bangalore.
Associate Professor, Institute of Nephro-Urology, Bangalore.
Medical practice
1994 – 2000
2000 – 2003
2003 – / Practiced at a very large dialysis center based at the Division of Nephrology, Department of Internal Medicine at the Long Island College Hospital, New York encompassing more than 1000 dialysis patients at any given time including 100 peritoneal dialysis patients. It is one of the largest and longest running dialysis programs in the United States.
Practiced at a large Nephrology practice in Florida, affiliated with the busiest cardiovascular surgical program in state of Florida.
ConsultantNephrologist, Bangalore, India.
WockhardtHospital, The BangaloreHospital,andSagarApolloHospital.
Additional clinical training
2002
2003
2003 / Transplantation Mini-fellowship, Life Link Transplant Institute, Tampa, Florida.
Y-Tec Peritonioscopic PD catheter implantation, Lafeyette, Indiana.
Renal Ultrasound Course, NKF Spring Clinical Meeting, Dallas, Texas.
Medical Licenses
1987
1990
1991
1995
2000 /
  • Karnataka, India, No. 25932
  • Maryland, USA, No. D40572
  • Tennessee, USA, No. MD021984
  • New York, USA, No. 201322
  • Florida, USA, No. ME80037

Professional memberships
1988 – 2003
1989 – 2003
1992 – 2004
1993 – 2004
1994 –
2003 –
2004 –
2006 –
2008 – / American Society of Internal Medicine.
AmericanCollege of Physicians.
National Kidney Foundation, USA.
American Society of Nephrology.
International Society of Nephrology.
Association of Physicians of India-Karnataka chapter
Indian Society of Nephrology-Southern Chapter
Indian Medical Association
Indian Society of Nephrology
Additional professional activities
1994 –
1995
1996 –
1996 – 2000
1997 – 2000
2001 – 2004
2004 –
2004 – 2007
2006 – / Manuscript Reviewer, Kidney International.
Abstract reviewer, 28th Annual Meeting of the American Society of Nephrology.
Manuscript Reviewer, American Journal of Kidney Diseases.
Member, Institutional Review Board, The Long IslandCollegeHospital.
Vice Chairman, Institutional Review Board, The Long IslandCollegeHospital.
Medical Director, Outcomes Research International, Inc.
Medical Director, Outcomes Clinical Research India, Bangalore.
Member, Ethics Committee, Clinigene, Bangalore, India.
Member, Independent Ethics Committee Consultants, Bangalore, India.
Research Experience (IN CHRONOLOGICAL ORDER)
1992 – 94
1994 – 2000
1994 – 2000
1996
1996 – 99
1996 – 2001
1996 – 2000
1997 – 2000
1998 – 2000
1999
2000
2000
2000 – 2001
2001 – 2002
2001 – 2003
2002 – 2003
2002 – 2003
2003 –
ongoing
2003–2004
2005 –
ongoing
2005 – 2006 / Recipient of Research Fellowship Award from the National Kidney Foundation, USA. Mentor: Raymond M Hakim, MD, PhD. Professor of Medicine, VanderbiltUniversityMedicalCenter, Nashville, TN. The topics of interest during the research fellowship years included:
Study of uremic platelet dysfunction using a novel device to measure shear-induced platelet aggregation and calcium flux; flow-cytometry to study platelet surface receptors involved in platelet aggregation; effect of hemodialysis procedure and dialyzer membrane on platelet function in uremic patients.
Study of elastin peptide levels in hemodialysis patients to understand the effects of membrane biocompatibility on elastin metabolism in uremia.
Study the mechanism(s) of decreased erythrocyte survival in uremia. Study the effects of membrane attack complex (C5b-9) on the fragility of erythrocyte and the effects of various dialysis membranes.
Predictors of survival in end-stage renal disease. Effects of dialysis dose, nutritional indices and demographic variables on patient survival in hemodialysis and peritoneal dialysis.
Lipoprotein(a) levels in CAPD and HD patients and its relationship with cardiovascular morbidity and mortality.
Co-Principal Investigator, Normal Hematocrit Cardiac Study (sponsored by AMGEN). Protocol No. EPO-930107. Multi-center Phase III clinical trial to determine the effects of normal versus anemic hematocrit in hemodialysis patients with cardiac disease.
Co-Principal Investigator, Pimagedine Study (sponsored by Alteon, Inc., Ramsey, NJ). Protocol No. 201228-PR0014. Multi-center Phase II & Phase III placebo-controlled safety and efficacy study of Pimagedine in Diabetic Patients with ESRD on Hemodialysis.
Co-Principal Investigator, Losartan Renal Study (RENAAL) (sponsored by Merck & Co., Inc.). Protocol No. 147-00. Multi-center, double-blind, randomized, placebo-controlled study to evaluate the renal protective effects of Losartan in patients with non-insulin dependent diabetes mellitus and nephropathy.
Co-Principal Investigator, Iron Deficient Erythropoiesis and effectiveness of Iron therapy in ESRD patients treated with rHuEPO: Analysis of reticulocyte hemoglobin content (CHr) (sponsored by Bayer Diagnostics).
Principal Investigator, Evaluation of CHr in Anemia Management in PD.
Adequacy in Peritoneal Dialysis: Effects of residual renal function and delivered creatinine clearance on patient morbidity and mortality.
Principal Investigator. An open label, randomized study of Novel Erythropoiesis Stimulating Protein and recombinant human erythropoietin for the treatment of anemia in patients with end-stage renal disease receiving dialysis (Phase II study, Protocol No. 980211, sponsored by AMGEN)
Principal Investigator. A randomized study comparing the efficacy of once weekly versus 3 times weekly administration of Intravenous Novel Erythropoiesis stimulating protein to subjects with end-stage renal disease receiving hemodialysis (Phase III study, Protocol No. 990773, sponsored by AMGEN)
Principal Investigator. A randomized study comparing the efficacy of once weekly versus 3 times weekly administration of Subcutaneous Novel Erythropoiesis stimulating protein to subjects with end-stage renal disease receiving hemodialysis (Phase III study, Protocol No. 990787, sponsored by AMGEN)
Co-Principal Investigator. A randomized, double blind, parallel group evaluation of usual care plus Cerivastatin 0.4 mg once daily compared with usual care (placebo) alone in patients with end-stage renal disease new to hemodialysis: Cerivastatin Heart Outcomes in Renal disease: Understanding Survival. (CHORUS Study No. 100253, sponsored by BAYER, Inc.)
Co-Principal Investigator. Study of Lanthanum carbonate as a phosphate binder in chronic hemodialysis patients.
Principal Investigator. A Phase 3 Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG073) in Secondary Hyperparathyroidism of End Stage Renal Disease Treated with Hemodialysis (Protocol number 20000172, sponsored by AMGEN).(Published: BlockGA et al. NEnglJMed 2004: 350; 1516-25)
Principal Investigator. A Randomized Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of a Calcimimetic Agent (AMG073) in Subjects with Secondary Hyperparathyroidism of Chronic Renal Insufficiency (Phase 2 study, Protocol number 20010239, sponsored by AMGEN).(Published: Charytan C, et al: Cinacalcethydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receivingdialysis.Am J Kidney Dis 46:58-67, 2005)
Principal Investigator. A Placebo-controlled-, Double-blind, Extension Study to Assess the Long-term Safety of an Oral Calcimimetic Agent (AMG073) in Secondary Hyperparathyroidism of End-stage Renal Disease (Phase 3 study, Protocol number 20010240, sponsored by AMGEN).
Prospective evaluation and management of diabetes, hypertension and proteinuria in a rural population (25,000) in Karnataka with special interest to minimize end-organ damage.
Investigation of Adequacy, Nutritional & Peritoneal transport Characteristics in Indian Peritoneal Dialysis Patients: Indian Adequacy Study Group. (Sponsored Baxter International)
Screening and Early Evaluation of Kidney Disease Project (SEEK). A prospective multicenter project to gather data regarding chronic kidney disease (CKD) in India in collaboration with HarvardMedicalSchool, Boston, USA.
An open-label prospective study to evaluate the efficacy and safety of rHuEPO (Biocon) in patients either on dialysis or non-dialysis for the management of anemia of chronic kidney disease. Sponsored by Biocon, Bangalore, India.
RESEARCH GRANTS AWARDED
1993 – 95
1996
1997 / National Kidney Foundation of USA (Research Fellowship Award).
National Kidney Foundation of NY/NJ (Young Investigator Award).
National Kidney Foundation of NY/NJ (Young Investigator Award).
Publications

Journal Articles

  1. Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM. Antiplatelet therapy in graft thrombosis: Results of a prospective, randomized, double blind study. Kidney Int 1994;45:1477-83
  1. Sreedhara R, Itagaki I, Lynn B, Hakim RM. Defective platelet aggregation in uremia is transiently worsened by hemodialysis. Am J Kidney Dis 1995;25:555-563
  1. Sreedhara R, Itagaki I, Hakim RM. Uremic patients have decreased shear-induced platelet aggregation mediated by decreased GP IIb-IIIa receptors. Am J Kidney Dis 1996;27:355-364
  1. Avram MM, Sreedhara R, Patel N, Chattopadhyay J, Thu T, Fein PA. Is an elevated level of serum lipoprotein (a) a risk factor for cardiovascular disease in CAPD patients?Adv Perit Dial 1996;12:266-271
  1. Avram MM, Bonomini LV, Sreedhara R, Mittman N. Predictive Value of Nutritional Markers (Albumin, Creatinine, Cholesterol and Hematocrit) for Patients on Dialysis for up to 30 Years. Am J Kidney Dis 1996;28:910-917
  1. Avram MM, Sreedhara R, Avram DK, Muchnick RA, Fein P.. Enrollment Parathyroid Hormone Level is a New Marker of Survival in Hemodialysis and Peritoneal Dialysis Therapy for Uremia. Am J Kidney Dis 1996;28:924-930
  1. Sreedhara R, Avram MM, Blanco M, Batish R, Mittman N. Pre-albumin is the Best Nutritional Predictor of Survival in Dialysis. Am J Kidney Dis 1996;28:937-942
  1. Mittman N, Sreedhara R, Mushnick R, Chattopadhyay J, Zelmonovic D, Vaseghi M, Avram MM. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. Am J Kidney Dis 1997;30:912-922
  1. Ismail N, Sreedhara R. Ischemic Renal Disease (Review). J Med Liban. 1998 Jan-Feb;46(1):29-35.
  2. Avram MM, Sreedhara R, Mittman N: Long term survival in end-stage renal disease. Dial Transplant 1998;27:11-21
  1. Avram MM, Sreedhara R, Chattopadhyay J. Dialysis in Diabetic Patients: Three Decades of Experience, from 1964 to 1997, Nephrol Dial Transplant 1998.
  1. Sreedhara R. Characteristics of peritonitis in HIV-positive PD patients.Semin Dial. 2000 Sep-Oct; 13(5):338.
  2. Avram MM, Sreedhara R, Fein PA, Oo KK, Chattopadhyay J, Mittman N. Survival on hemodialysis and peritoneal dialysis over twelve years with emphasis on nutritional parameters. Am J Kidney Dis, S-77-81, 2001.
  1. Antithrombotic Trialists’ Collaboration. Prevention of death, myocardial infarction and stroke by antiplatelet therapy: Collaborative meta-analysis of 266 trials involving 200,000 patients at high risk of occlusive vascular events. BMJ 2001.

Book Chapter

1. Avram MM, Sreedhara R: Morbidity and Mortality in Hemodialysis in Textbook of Nephrology editors: Massry and Glassock, Fourth Edition, pages 1505-1519, publisher WilliamsWilkins, New York, 2001.

JOURNAL ARTICLE PUBLICATIONS FROM PARTICIPATED CLINICAL TRIALS

1.BlockGA, et al. Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis. N Engl J Med 2004;350:1516-25.
2.Charytan C, et al. Cinacalcet Hydrochloride is an Effective Treatment for SecondaryHyperparathyroidism in Patients with CKD Not Receiving Dialysis. Am J Kidney Dis 2005;46:58-67
3.Achieving NKF-K/DOQITM bone metabolism and disease treatment goals with Cinacalcet HCl. Moe SM et al. Kidney Int 2005;67:760–771
4.

Abstracts

  1. Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM. Antiplatelet Therapy in expanded polytetrafluoroethylene graft thrombosis: Results of a randomized double blind study. J Am Soc Nephrol 1993;4:388
  1. Sreedhara R, Itagaki I, Hakim RM. Defective platelet aggregation in uremia is transiently worsened by hemodialysis. J Am Soc Nephrol 1993;4:388
  1. Sreedhara R, Davidson JM, Himmelfarb J, McMonagle E, Hakim RM. Dialysis patients have high concentrations of elastin peptides which are influenced by membrane biocompatibility. J Am Soc Nephrol 1993;4:388
  1. Sreedhara R, Itagaki I, Hakim RM. Decreased platelet aggregation in renal failure may be mediated by decrease in platelet surface receptors involved in aggregation. J Am Soc Nephrol 1993;4:432
  1. Sreedhara R, Itagaki I, Hakim RM. Shear-induced platelet aggregation in Uremia. Proceedings of AAMI Cardiovascular Science and Technology Conference, Dec, 1993
  1. Sreedhara R, Avram MM, Fein P, Javed M, Mittman N. CAPD patients with cardiovascular disease have increased Lp(a) levels which may be associated with decreased survival. J Am Soc Nephrol 1995;6:588
  1. Mittman N, Avram MM, Castanares A, Oo K, Licht J, Sreedhara R. Severe Neuropathy predicts mortality in non-diabetic hemodialysis patients. J Am Soc Nephrol 1995;6:552
  1. Mittman N, Avram MM, Loutoby R, Sreedhara R. Association of serum bicarbonate to survival in hemodialysis: a non-linear relationship. J Am Soc Nephrol 1995;6:552
  1. Mittman N, Avram MM, Bonomini L, Oo K, Licht J, Sreedhara R. Hemodialysis treatment dose is an independent determinant of seven year survival. J Am Soc Nephrol 1995;6:610
  1. Zafar S, Jorden A, Fein PA, Sreedhara R, Avram MM, Chattopadhyay J. Is elevated Lp(a) a risk factor for cardiovascular disease in CAPD patients ? 16th Annual Conference on Peritoneal Dialysis, Seattle, Feb 21-23, 1996. Perit Dial Int 1996;16:S63
  1. Patel N, Thu T, Fein PA, Sreedhara R, Genabe MI, Avram MM. Importance of demographic and nutritional markers as predictors of long-term mortality risk in peritoneal dialysis patients. Perit Dial Int 1996;16:S29
  1. Avram MM, Mittman N, Patel N, Chattopadhyay J, Sreedhara R. Predictors of long-term survival in hemodialysis: Eight years of prospective follow-up. ASAIO, May 2-4, WashingtonDC. ASAIO J 1996;42:80
  1. Mittman N, Avram MM, Oo K, Licht J, Sreedhara R. Severe neuropathy and urea reduction ratio independently predict mortality in non-diabetic hemodialysis patients. ASAIO J 1996;42:80
  1. Patel N, Avram MM, Mittman N, Sreedhara R. Predictors of long-term survival in hemodialysis: Eight years of prospective follow-up. NKF fifth annual Spring Clinical Nephrology meeting, Anheim, CAApril 25-28, 1996
  1. Avram MM, Patel N, Mittman N, Sreedhara R. Predictors o long term survival in Hemodialysis. Eight years of prospective follow-up. EDTA 33rd Congress of the European Renal Association/EDTA, June 18-21, 1996, Amsterdam
  1. Avram MM, Sreedhara R, Batish R, Chattopadhyay J, Mittman N. Characteristics of Very Long-term Survivors on Hemodialysis; Survival up to 30 Years. J Am Soc Nephrol 1996;7:1437
  2. Sreedhara R, Avram MM, Patel N, Ganzon R, Chattopadhyay J, Fein PA. Correlates of Very Long Term Survival in Peritoneal Dialysis Patients. J Am Soc Nephrol 1996;7:1465
  1. Avram MM, Sreedhara R, Fein PA, Mittman N. Prealbumin Is the Single Best Indicator of Nutritional Status and Prognosis in Dialysis Patients. J Am Soc Nephrol 1996;7:1437
  2. Avram MM, Sreedhara R, Ukiomogbe C, Thu T, Mittman N. Serum Intact Parathyroid Hormone Is a New Independent Predictor of Mortality in Hemodialysis Patients. J Am Soc Nephrol 1996;7:1438
  1. Sreedhara R, Avram MM, Fein PA, Batish R, Chattopadhyay J, Mittman N. Enrollment Serum Intact Parathyroid Hormone Independently Predicts Mortality in Peritoneal Dialysis Patients. J Am Soc Nephrol 1996;7:1464
  1. Mittman N, Avram MM, Thu T, Oo K, Bonomini L, Sreedhara R. Predictors of mortality in hemodialysis: Analysis of serial data over six years. J Am Soc Nephrol 1996;7:1523
  1. Mittman N, Avram MM, Blanco M, Ganzon R, Sreedhara R. Severe Sensory Neuropathy and urea reduction ratio independently predict mortality in non-diabetic hemodialysis patients. J Am Soc Nephrol 1996;7:1458
  1. Avram MM, Sreedhara R, Fein PA, Mittman N. Prealbumin is the single best indicator of nutritional status in hemodialysis. 8th International Congress on Nutrition and Metabolism in Renal Disease. Naples, Italy, October 9- 12, 1996.
  1. Avram MM, Sreedhara R, Chattopadhyay J, Mittman N. Serum intact PTH is a new independent predictor of mortality in Hemodialysis patients. 8th International Congress on Nutrition and Metabolism in Renal Disease. Naples, Italy, October 9- 12, 1996.
  1. Avram MM, Sreedhara R, Chattopadhyay J, Mittman N. Characteristics of survival up to 30 years on hemodialysis. 8th International Congress on Nutrition and Metabolism in Renal Disease. Naples, Italy, October 9- 12, 1996.
  1. Ramaswamy CR, Fein PA, Avram D, Chattopadhyay J, Sreedhara R, Avram MM. Incidence and spectrum of Peritonitis in HIV Positive Peritoneal Dialysis Patients. 17th Annual Conference on Peritoneal Dialysis, Denver, Feb 16-18, 1997
  1. Fein PA, Sreedhara R, Mittman N, Thu T, Avram MM. Characteristics of Long Term Survivors on Peritoneal Dialysis. 17th Annual Conference on Peritoneal Dialysis.
  1. Avram MM, Fein PA, Sreedhara R, Batish R, Avram D, Mittman N. Enrollment intact parathyroid hormone, a new important marker for survival in Peritoneal Dialysis. 17th Annual Conference on Peritoneal Dialysis.
  1. Avram MM, Fein PA, Blanco M, Sreedhara R, Mittman N. Prealbumin, an important predictor for survival and nutritional status in Peritoneal Dialysis. 17th Annual Conference on Peritoneal Dialysis.
  1. Blanco M, Avram MM, Mittman N, Sreedhara R. Importance of Prealbumin as Predictor of Survival in dialysis Patients. The National Kidney Foundation, Sixth Annual Spring Clinical Nephrology Meetings, Dallas, TX, CA April 17-20, 1997.
  1. Avram MM, Sreedhara R, Mittman N. Prealbumin is a strong predictor of nutritional risk and five year mortality in dialysis patients. ASAIO J 1997;26:77
  1. Avram MM, Sreedhara R, Mittman N. Enrollment serum intact parathyroid hormone is a new marker for survival in hemodialysis patients. ASAIO J 1997;26:78
  1. Avram MM, Sreedhara R, Batish R, Mushnick R, Mittman N. Survival of hemodialysis up to 30 years: Characteristics and biochemical profile.14th International Congress of Nephrology, Sydney, Australia, May 25-29, 1997.
  1. Avram MM, Sreedhara R, Thu T, Mushnick R, Mittman N. Enrollment serum Intact Parathyroid Hormone, is a new marker for survival in hemodialysis patients.14th International Congress of Nephrology, Sydney, Australia, May 25-29, 1997.
  1. Avram MM, Sreedhara R, Fein PA, Mushnick R, Mittman N. Prealbumin is a strong predictor of nutritional risk and five year mortality in dialysis patients.14th International Congress of Nephrology, Sydney, Australia, May 25-29, 1997.
  1. Sreedhara R, Mittman N, Chattopadhyay J, Avram MM. Reticulocyte Hemoglobin correlates with Traditional Iron Indices in Hemodialysis Patients. Annual meeting of the American Society of Nephrology 1997.
  1. Mittman N, Sreedhara R, Thomas A, Avram MM. Reticulocyte Hemoglobin: Earlier and more sensitive detection of functional deficiency in Hemodialysis patients. Annual meeting of the American Society of Nephrology, 1997.
  1. Ramaswamy CR, Sreedhara R, Fein PA, Dedios A, Avram MM. Characteristics of Peritonitis in HIV infected patients treated with Peritoneal dialysis. Annual meeting of the American Society of Nephrology, 1997.
  1. Avram M.M., Fein P, Purohit N, Sreedhara R. Survival and Predictive Markers for Longevity in diabetic and Non-diabetic Patients on Peritoneal dialysis. 18th Annual Conference on Peritoneal Dialysis, Nashville, Feb 23-25, 1998.
  1. Ramaswamy CR, Sreedhara R, Fein P, Bista A, Chattopadhyay J, Wright P, Avram MM. Evaluation of Reticulocyte Hemoglobin content in Anemia treatment among Peritoneal Dialysis Patients.18th Annual Conference on Peritoneal Dialysis, Nashville, Feb 23-25, 1998.
  1. Bista AB, Sreedhara R, Avram MM. Ten years Survival of Diabetic and Non-diabetic Patients on Hemodialysis. National Kidney Foundation, 7th Annual Spring Clinical Nephrology Meetings, Nashville, March 26-29, 1998.
  1. Ramaswamy CR, Sreedhara R, Fein PA, Chattopadhyay J, Bista A, Avram MM. Reticulocyte Hemoglobin Content is a better Marker of Functional Iron Deficiency in Peritoneal Dialysis. American Society of Nephrology, Annual meeting Oct 1998, Philadelphia, PA.
  1. Mittman N, Sreedhara R, Thomas A, Prabhakara M, Avram MM. Prospective Evaluation of Reticulocyte Hemoglobin Content to Predict Functional Iron Deficiency in Hemodialysis. American Society of Nephrology, Annual meeting Oct 1998, Philadelphia, PA.
  1. Sreedhara R, Ramaswamy CR, Bista AB, Oo KK, Fein PA, Mittman N. Reticulocyte hemoglobin content (CHr) predicts functional iron deficiency in peritoneal dialysis patients receiving erythropoietin.19th Annual Conference on Peritoneal Dialysis, Charlotte, North Carolina, Feb 28-March 2, 1999. (Slide presentation)
  1. Sreedhara R, Mahankali B, Tachopoulou O, Prabhakara M, Chattopadhyay J, Jorden L, Fein PA, Avram MM. Effect of dialysis dose on morbidity & Mortality : Five year study in peritoneal dialysis.19th Annual Conference on Peritoneal Dialysis, Charlotte, North Carolina, Feb 28-March 2, 1999.
  1. Avram MM, Fein PA, Martinez C, Sreedhara R.